Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Glycan array data management at Consortium for Functional Glycomics.

Venkataraman M, Sasisekharan R, Raman R.

Methods Mol Biol. 2015;1273:181-90. doi: 10.1007/978-1-4939-2343-4_13.

PMID:
25753711
2.

Heparin and heparan sulfate: analyzing structure and microheterogeneity.

Shriver Z, Capila I, Venkataraman G, Sasisekharan R.

Handb Exp Pharmacol. 2012;(207):159-76. doi: 10.1007/978-3-642-23056-1_8. Review.

3.

Chinese hamster ovary cells can produce galactose-α-1,3-galactose antigens on proteins.

Bosques CJ, Collins BE, Meador JW 3rd, Sarvaiya H, Murphy JL, Dellorusso G, Bulik DA, Hsu IH, Washburn N, Sipsey SF, Myette JR, Raman R, Shriver Z, Sasisekharan R, Venkataraman G.

Nat Biotechnol. 2010 Nov;28(11):1153-6. doi: 10.1038/nbt1110-1153. No abstract available. Erratum in: Nat Biotechnol. 2011 May;29(5):459.

4.

M118--a rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes.

Kishimoto TK, Qi YW, Long A, Capila I, Sasisekharan R, Guerrero L, Fier I, Roach J, Venkataraman G.

Thromb Haemost. 2009 Nov;102(5):900-6. doi: 10.1160/TH09-02-0105.

PMID:
19888526
5.

Minimum FGF2 binding structural requirements of heparin and heparan sulfate oligosaccharides as determined by NMR spectroscopy.

Guglier S, Hricovíni M, Raman R, Polito L, Torri G, Casu B, Sasisekharan R, Guerrini M.

Biochemistry. 2008 Dec 30;47(52):13862-9.

PMID:
19117094
6.

Outbreak of adverse reactions associated with contaminated heparin.

Blossom DB, Kallen AJ, Patel PR, Elward A, Robinson L, Gao G, Langer R, Perkins KM, Jaeger JL, Kurkjian KM, Jones M, Schillie SF, Shehab N, Ketterer D, Venkataraman G, Kishimoto TK, Shriver Z, McMahon AW, Austen KF, Kozlowski S, Srinivasan A, Turabelidze G, Gould CV, Arduino MJ, Sasisekharan R.

N Engl J Med. 2008 Dec 18;359(25):2674-84. doi: 10.1056/NEJMoa0806450. Epub 2008 Dec 3. Erratum in: N Engl J Med. 2010 Mar 18;362(11):1056.

7.

Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events.

Guerrini M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A, Capila I, Lansing JC, Guglieri S, Fraser B, Al-Hakim A, Gunay NS, Zhang Z, Robinson L, Buhse L, Nasr M, Woodcock J, Langer R, Venkataraman G, Linhardt RJ, Casu B, Torri G, Sasisekharan R.

Nat Biotechnol. 2008 Jun;26(6):669-75. doi: 10.1038/nbt1407. Epub 2008 Apr 23.

8.

Contaminated heparin associated with adverse clinical events and activation of the contact system.

Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Venkataraman G, Austen KF, Woodcock J, Sasisekharan R.

N Engl J Med. 2008 Jun 5;358(23):2457-67. doi: 10.1056/NEJMoa0803200. Epub 2008 Apr 23. Erratum in: N Engl J Med. 2010 Mar 18;362(11):1056.

9.

The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.

Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J, Yaccoby S, Shaughnessy JD Jr, Barlogie B, Sanderson RD.

Blood. 2007 Sep 15;110(6):2041-8. Epub 2007 May 29.

10.

Crystal structure of heparinase II from Pedobacter heparinus and its complex with a disaccharide product.

Shaya D, Tocilj A, Li Y, Myette J, Venkataraman G, Sasisekharan R, Cygler M.

J Biol Chem. 2006 Jun 2;281(22):15525-35. Epub 2006 Mar 24.

11.

Advancing glycomics: implementation strategies at the consortium for functional glycomics.

Raman R, Venkataraman M, Ramakrishnan S, Lang W, Raguram S, Sasisekharan R.

Glycobiology. 2006 May;16(5):82R-90R. Epub 2006 Feb 14. Review.

PMID:
16478800
12.

Glycomics: an integrated systems approach to structure-function relationships of glycans.

Raman R, Raguram S, Venkataraman G, Paulson JC, Sasisekharan R.

Nat Methods. 2005 Nov;2(11):817-24. Review.

PMID:
16278650
13.

HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo.

Dai Y, Yang Y, MacLeod V, Yue X, Rapraeger AC, Shriver Z, Venkataraman G, Sasisekharan R, Sanderson RD.

J Biol Chem. 2005 Dec 2;280(48):40066-73. Epub 2005 Sep 27.

14.

Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route.

Qi Y, Zhao G, Liu D, Shriver Z, Sundaram M, Sengupta S, Venkataraman G, Langer R, Sasisekharan R.

Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9867-72.

15.

Quantitative assessment of FGF regulation by cell surface heparan sulfates.

Berry D, Shriver Z, Venkataraman G, Sasisekharan R.

Biochem Biophys Res Commun. 2004 Feb 20;314(4):994-1000.

PMID:
14751231
18.

Structural specificity of heparin binding in the fibroblast growth factor family of proteins.

Raman R, Venkataraman G, Ernst S, Sasisekharan V, Sasisekharan R.

Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2357-62. Epub 2003 Feb 25.

19.

Rational design of low-molecular weight heparins with improved in vivo activity.

Sundaram M, Qi Y, Shriver Z, Liu D, Zhao G, Venkataraman G, Langer R, Sasisekharan R.

Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):651-6. Epub 2003 Jan 13.

20.

The heparin/heparan sulfate 2-O-sulfatase from Flavobacterium heparinum. Molecular cloning, recombinant expression, and biochemical characterization.

Myette JR, Shriver Z, Claycamp C, McLean MW, Venkataraman G, Sasisekharan R.

J Biol Chem. 2003 Apr 4;278(14):12157-66. Epub 2003 Jan 7.

Supplemental Content

Loading ...
Support Center